IRS2 and metabolic dysfunction-associated steatohepatitis: It was reported that patients with HCC have genetic alterations (e.g., mutations, fusion, deletions, amplifications, or single nucleotide polymorphisms) in several genes, and genes previously identified as key players in the NASH progression and also implicated in liver cancer, showed genetic alterations, especially mutations in five genes (DGAT1, FASN, LPL, IRS2, and YWHAZ), which are implicated in lipid synthesis, insulin resistance, and cancer progression [94]; thus, these genomic alterations are contributing in the progression of the disease from NASH to HCC.